Novo Nordisk Partners With Anthropic: How Claude Could Change the Future of Drug Development

Artificial intelligence is moving deeper into the pharmaceutical industry, and the latest example comes from Novo Nordisk and Anthropic.

Novo Nordisk, the Danish pharmaceutical company behind medicines such as Ozempic and Wegovy, has partnered with Anthropic to explore how its Claude AI models can help accelerate drug discovery and development.

The companies announced the collaboration on September 16, 2026, with the focus on using AI to tackle scientific and research challenges and build new AI-powered workflows for pharmaceutical development.

But what does this actually mean for the drug industry?

What Is the Novo Nordisk-Anthropic Partnership?

The partnership is designed to bring Anthropic's Claude models into selected research and development workflows at Novo Nordisk.

Novo plans to test Claude Science, Anthropic's science-focused capabilities, for scientific problems and drug-discovery work. The companies also intend to develop targeted AI solutions for challenges identified by Novo's researchers.

Another area of the collaboration involves AI-assisted software development.

In simple terms, Novo is not simply using Claude as a chatbot. The objective is to integrate AI into parts of the scientific and technical workflow where researchers and developers spend significant amounts of time analyzing information, writing, coding and solving complex problems.

Why Is AI Becoming Important in Drug Development?

Developing a new medicine is a long and complicated process.

Researchers need to study biology, identify potential drug targets, evaluate molecules, analyze experimental results and eventually conduct clinical trials before a medicine can reach patients.

A major challenge is the enormous amount of information involved.

AI systems can potentially help researchers organize and analyze large quantities of scientific information much faster, identify relationships within datasets and assist with repetitive research tasks.

That does not mean AI can independently invent and approve a medicine.

Instead, the technology can act as an additional tool for scientists, helping them move through certain stages of research more efficiently.

The pharmaceutical industry has increasingly been experimenting with AI for target discovery, molecule design, clinical-trial planning and regulatory work. Reuters reported earlier this year that drugmakers are increasingly investing in AI in an effort to reduce development time and improve R&D efficiency.

Claude Is Already Being Tested Inside Novo Nordisk

The Anthropic partnership builds on existing work between Claude and Novo Nordisk.

Anthropic says Novo has already used Claude Code to develop NovoScribe, an AI-powered system designed to assist with clinical and regulatory documentation.

According to Anthropic, Novo reduced the time required to produce certain clinical study documentation from more than 10 weeks to around 10 minutes, while also reporting substantial reductions in resources required for some device verification protocols.

This is important because pharmaceutical development involves enormous amounts of documentation.

Clinical studies can generate hundreds of pages of information, while regulatory submissions require extensive technical material.

Automating parts of this work could allow scientists and other specialists to spend more time on research rather than repetitive documentation.

From Documentation to Drug Discovery

The new collaboration goes beyond paperwork.

The companies want to explore Claude's capabilities for scientific problems and drug discovery itself.

This is potentially a much bigger opportunity.

Anthropic has recently published research describing experiments involving Claude and protein design as well as analytical chemistry. In one reported experiment, Claude-generated protein binders showed measurable binding success across a set of targets.

These developments illustrate why pharmaceutical companies are interested in advanced AI models.

If AI can help scientists evaluate potential biological targets, analyze experimental information or design and test ideas more quickly, the technology could become part of the early research process.

However, laboratory validation remains essential. An AI-generated hypothesis or molecule is not automatically a successful medicine.

Novo Is Building a Wider AI Strategy

The Anthropic agreement is not Novo Nordisk's only major AI initiative.

In April 2026, Novo announced a partnership with OpenAI covering areas including drug discovery, manufacturing, supply chains and business operations.

In August, Novo also announced a strategic partnership with Amazon Web Services that includes an AI co-innovation hub in London focused on drug discovery and technology infrastructure.

Taken together, these initiatives show that Novo is experimenting with several forms of AI technology rather than relying on a single AI provider.

What Could Change for Pharmaceutical Research?

If these technologies prove effective at scale, several parts of pharmaceutical R&D could change.

Faster information analysis

Scientists could use AI to examine large collections of scientific literature, experimental information and internal research data more efficiently.

More rapid hypothesis generation

AI could help researchers generate and compare potential explanations or research directions before laboratory testing.

Faster software development

Researchers increasingly need specialized software and data tools. AI coding systems could help scientific teams build prototypes and internal applications faster.

Less administrative work

AI could automate portions of clinical documentation and regulatory preparation, reducing the amount of repetitive work required from research teams.

More experimentation

When certain research tasks become faster and cheaper, teams may be able to test more ideas within the same period.

AI Will Not Remove the Need for Scientists

One of the most important points is that AI does not eliminate the need for human scientific expertise.

Drug development involves biological uncertainty, laboratory experiments, clinical evidence, safety assessments and regulatory requirements.

AI can generate suggestions and analyze information, but scientists still need to determine whether those suggestions make biological sense and whether they can be validated experimentally.

Novo's previous work with Claude also emphasizes controlled use of AI in a highly regulated environment, including data governance and human review.

Why This Partnership Matters

The Novo Nordisk-Anthropic agreement is part of a broader shift in pharmaceutical research.

AI is gradually moving from being a general productivity tool toward becoming part of the scientific workflow itself.

For Novo Nordisk, the potential attraction is straightforward: if researchers can analyze information, develop software, document studies and investigate scientific questions faster, the company may be able to make its R&D process more efficient.

For Anthropic, working with a major pharmaceutical company provides an opportunity to demonstrate how advanced AI models can be applied to highly technical scientific problems.

The bigger question is whether these tools can consistently translate faster digital work into better scientific discoveries.

That will ultimately be determined not by AI-generated text or impressive demonstrations, but by laboratory results, clinical evidence and medicines that successfully make it through the development process.

The Bigger Picture

The pharmaceutical industry is entering an increasingly AI-driven phase.

Novo Nordisk's partnerships with Anthropic, OpenAI and AWS show how major drugmakers are exploring different AI technologies across research, development and operations.

The latest Anthropic agreement therefore represents more than another AI partnership.

It is another sign that the race to develop new medicines is increasingly becoming a race to combine human scientific expertise with increasingly capable AI systems.

The technology is unlikely to replace the traditional drug-development process overnight. But if AI can shorten even selected parts of that process, it could change how pharmaceutical research teams work and how quickly promising ideas move from computer screens to laboratories and, eventually, patients.